Chemoinformaics analysis of (+)-erythratidinone
| Molecular Weight | 329.396 | nRot | 3 |
| Heavy Atom Molecular Weight | 306.212 | nRig | 21 |
| Exact Molecular Weight | 329.163 | nRing | 4 |
| Solubility: LogS | -2.516 | nHRing | 2 |
| Solubility: LogP | 1.754 | No. of Aliphatic Rings | 3 |
| Acid Count | 0 | No. of Aromatic Rings | 1 |
| Base Count | 1 | No. of Aliphatic Carbocycles Rings | 1 |
| Atoms Count | 47 | No. of Aliphatic Hetero Cycles | 2 |
| No. of Heavy Atom | 24 | No. of Aromatic Carbocycles | 1 |
| nHetero | 5 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 23 | No. of Saturated Hetero Cycles | 1 |
| No. of Carbon atom | 19 | No. of Saturated Rings | 1 |
| No. of Nitrogen atom | 1 | No. of Arom Atom | 6 |
| No. of Oxygen atom | 4 | No. of Arom Bond | 6 |
| nHA | 5 | APOL | 51.3742 |
| nHD | 0 | BPOL | 30.8598 |
| QED | 0.85 |
| Synth | 4.18 |
| Natural Product Likeliness | 1.829 |
| NR-PPAR-gamma | 0.007 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Accepted |
| Pgp-inh | 0.994 |
| Pgp-sub | 0.108 |
| HIA | 0.004 |
| CACO-2 | -4.788 |
| MDCK | 0.0000244 |
| BBB | 0.985 |
| PPB | 0.533542 |
| VDSS | 1.513 |
| FU | 0.274294 |
| CYP1A2-inh | 0.025 |
| CYP1A2-sub | 0.651 |
| CYP2c19-inh | 0.059 |
| CYP2c19-sub | 0.962 |
| CYP2c9-inh | 0.051 |
| CYP2c9-sub | 0.509 |
| CYP2d6-inh | 0.032 |
| CYP2d6-sub | 0.761 |
| CYP3a4-inh | 0.065 |
| CYP3a4-sub | 0.938 |
| CL | 10.332 |
| T12 | 0.728 |
| hERG | 0.038 |
| Ames | 0.331 |
| ROA | 0.13 |
| SkinSen | 0.037 |
| Carcinogencity | 0.859 |
| EI | 0.009 |
| Respiratory | 0.934 |
| NR-Aromatase | 0.342 |
| Antiviral | No |
| Prediction | 0.579703 |